Comparative Pharmacology
Head-to-head clinical analysis: SULFAIR FORTE versus SULFALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAIR FORTE versus SULFALAR.
SULFAIR FORTE vs SULFALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate antagonist; inhibits dihydropteroate synthetase in bacterial folate synthesis pathway.
Sulfamethoxazole is a sulfonamide that competitively inhibits dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism in bacteria.
1-2 tablets (sulfamethoxazole 400 mg/trimethoprim 80 mg per tablet) orally every 12 hours.
Oral: 500 mg to 1 g every 12 hours; extended-release: 1 g every 12 hours. Intravenous: 1 g every 12 hours.
None Documented
None Documented
Approximately 10-12 hours in patients with normal renal function; prolonged in renal impairment (up to 20-30 hours), necessitating dose adjustment.
Terminal elimination half-life: 7-12 hours (prolonged in renal impairment up to 24-48 hours; clinical context: dosing interval adjustment needed for CrCl <30 mL/min)
Primarily renal excretion of unchanged drug (approx. 70-80%) and glucuronide conjugates; biliary excretion accounts for less than 20%; fecal elimination minimal.
Renal: approximately 70-80% as unchanged drug and acetylated metabolite; biliary/fecal: 20-30%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)